Business Wire (Free subscription) | 08/19/2008
MARLBOROUGH, Mass.--(BUSINESS WIRE)--Sepracor Inc. (Nasdaq: SEPR) today announced the appointment of two senior managers to key strategic and
Business Wire (Free subscription) | 07/29/2008
MARLBOROUGH, Mass.--(BUSINESS WIRE)--Sepracor Inc. (Nasdaq: SEPR) today announced its consolidated financial results for the second quarter and first half of 2008.
Market Watch (Free subscription) | 07/29/2008
Drug stocks climb in early action while shares of Sepracor Inc. tumble after it issues a disappointing 2008 financial forecast.
WBJournal.com (Free subscription) | 07/29/2008
Marlborough-based pharmaceutical company Sepracor Inc. said it saw second quarter revenue increase 6.3 percent to $294 million.
The Boston Business Journal (Free subscription) | 07/29/2008
A tax benefit helped Sepracor Inc. report a big boost in net income for its second quarter, but increased competition and changing government regulations prompted the company to offer mixed guidance for the remainder of the fiscal year.
Market Watch (Free subscription) | 07/29/2008
BOSTON (MarketWatch) -- Drug stocks climbed in early action Tuesday while shares of Sepracor Inc. tumbled after it issued a disappointing 2008 financial forecast. The Amex Pharmaceutical Index advanced 0.8% to 304.8 and the Amex Biotechnology Index rose 1.1% to 833.3. Sepracor shares sank 14% to $17.52. The pharmaceutical company said it now sees 2008 revenue coming in between...
EuroInvestor.co.uk (Free subscription) | 07/25/2008
Sepracor Inc. (Nasdaq: SEPR) will announce its second quarter 2008 financial results on July 29, 2008. In conjunction with the press release, Sepracor will host a conference call and l.. - Read more
Business Wire (Free subscription) | 07/25/2008
MARLBOROUGH, Mass.--(BUSINESS WIRE)--Sepracor Inc. (Nasdaq: SEPR) will announce its second quarter 2008 financial results on July 29, 2008. In conjunction with the press release, Sepracor
Business Wire (Free subscription) | 07/14/2008
MARLBOROUGH, Mass.--(BUSINESS WIRE)--Sepracor Inc. (Nasdaq: SEPR) today announced its intention to fully support the
PR News Wire (Free subscription) | 07/31/2008
MONTVALE, N.J., July 31 /PRNewswire-FirstCall/ -- Barr Pharmaceuticals, Inc. (NYSE: ) today confirmed that its subsidiaries, Barr Laboratories, Inc. and PLIVA-Hrvatska D.O.O., have initiated a challenge of the patent listed by UCB Inc. in connection with its Xyzal(R) Tablets (levocetirizine dihydrochloride), 5mg. The Company filed its Abbreviated New Drug Application (ANDA) containing...
